Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics Reports Full Year 2018 Results
Revenue increased 46% in 2018 compared to the prior year reflecting continued success growing the company’s profiling business with Pharma company customers TUCSON, Ariz. , March 07, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM) (HTG), a life science company whose mission
Toggle Summary HTG Molecular Diagnostics to Announce Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results and Host Conference Call on Thursday, March 7
TUCSON, Ariz. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the quarter and year ended December 31, 2018 after the market close
Toggle Summary HTG Molecular to Present Corporate Overview at the Cowen & Company 39th Annual Health Care Conference
TUCSON, Ariz. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that TJ Johnson, Chief Executive Officer, will present a corporate overview at the Cowen & Company 39th
Toggle Summary HTG Molecular Announces an Amendment and Extension to its Precision Diagnostic Partnership (PDP) Two
TUCSON, Ariz. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it has amended its second precision diagnostic partnership program (“PDP Two”) with QIAGEN Manchester Limited
Toggle Summary HTG Molecular to Present Corporate Overview at the 8th Annual SVB Leerink Global Healthcare Conference
TUCSON, Ariz. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that TJ Johnson, Chief Executive Officer, will present a corporate overview the 8 th Annual SVB Leerink

Stock Chart

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

Report of unscheduled material events or corporate event

Annual report which provides a comprehensive overview of the company for the past year

Report of unscheduled material events or corporate event